(MNTA)—PFE licenses Synthon’s generic-Copaxone ANDAs (20mg and 40mg doses) for US market: http://finance.yahoo.com/news/pfizer-synthon-enter-u-commercialization-123000551.html Under the terms of the agreement, Pfizer will have exclusive rights to commercialize both dosage formulations of Synthon’s glatiramer acetate in the United States. Synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate. Pfizer is solely responsible for the commercialization of glatiramer acetate in the United States. Financial terms of the agreement were not disclosed.